EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology

Yoh Watanabe iD, Tsukasa Baba iD, Shu Soeda, Hideki Tokunaga iD, Wataru Yamagami, Hiroyuki Nomura, Yoichi Kobayashi iD, Kei Kawana, Kiyoshi Yoshino, Yoshihito Yokoyama, Hirotaka Nishi iD, Hiroaki Kobayashi und 4 weitere

Journal of Obstetrics and Gynaecology Research · 2026

DOI: 10.1111/jog.70289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Yoh Watanabe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Obstetrics and Gynecology, Tohoku Medical and Pharmaceutical University, Sendai, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Despite advancements in maintenance therapies, recurrent epithelial ovarian cancer remains a clinical challenge with varying outcomes. This study aimed to evaluate the clinicopathological status and prognostic factors of patients with recurrent epithelial ovarian cancer.

Methods

We conducted a retrospective survey through the Committee on Gynecologic Oncology of the Japan Society of Gynecology and Obstetrics across 16 institutions.

Results

Histological subtypes included high‐grade serous (HGS; n = 304), clear‐cell (CC; n = 83), endometrioid (EM; n = 35), mucinous ( n = 12), and low‐grade serous ( n = 9) carcinomas. At recurrence, the median age was 61 years, 74.0% of patients had a platinum‐free interval (PFI) ≥ 6 months, and 78.8% maintained a performance status (PS) of 0. Genetic testing identified 42 BRCA1/2 mutations and 52 cases of homologous recombination deficiency positivity. Recurrence occurred primarily in the peritoneum, lymph nodes, and liver. For PFI ≥ 6 months, paclitaxel/carboplatin ± bevacizumab was the primary treatment; for PFI < 6 months, pegylated liposomal doxorubicin ± bevacizumab predominated. The overall response rate was 69.9% for PFI ≥ 6 months versus 17.7% for PFI < 6 months. Median overall survival was 27.9 months. Multivariate analysis confirmed histological subtype (CC/EM vs. HGS), PS, CA125 (≥ 100 U/mL), and PFI as significant independent prognostic factors, while first‐line molecularly targeted therapy use showed no significant impact.

Conclusion

PFI, histological subtype, PS, and CA125 levels are important prognostic factors for the use of molecular‐targeted agents for recurrent epithelial ovarian cancer. Patients with CC and EM subtypes experience worse outcomes than those with HGS, highlighting the need for subtype‐specific management in recurrent ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsNeoplasm Recurrence, LocalNeoplasms, Glandular and EpithelialHumansFemaleRetrospective StudiesJapanCarcinoma, Ovarian EpithelialPrognosisMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

antineoplastic agentmolecular targeted therapyneoplasm recurrenceovarian neoplasmsurveys and questionnaires

Autor:innen und Institutionen

  • Division of Obstetrics and Gynecology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
  • Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba, Japan.
  • Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan.
  • Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.

ORCID-Profile: Yoh Watanabe, Tsukasa Baba, Hideki Tokunaga, Yoichi Kobayashi, Hirotaka Nishi

Zitieren

APA

Watanabe, Y., Baba, T., Soeda, S., Tokunaga, H., Yamagami, W., Nomura, H., Kobayashi, Y., Kawana, K., Yoshino, K., Yokoyama, Y., Nishi, H., Kobayashi, H., Matsuzawa, Y., Oyamada, S., Takahashi, S., & Nagase, S. (2026). Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70289

Vancouver

Watanabe Y, Baba T, Soeda S, Tokunaga H, Yamagami W, Nomura H, et al. Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70289

BibTeX
@article{Watanabe2026,
  author = {Watanabe, Yoh and Baba, Tsukasa and Soeda, Shu and Tokunaga, Hideki and Yamagami, Wataru and Nomura, Hiroyuki and Kobayashi, Yoichi and Kawana, Kei and Yoshino, Kiyoshi and Yokoyama, Yoshihito and Nishi, Hirotaka and Kobayashi, Hiroaki and Matsuzawa, Yukiko and Oyamada, Shunsuke and Takahashi, Satoru and Nagase, Satoru},
  title = {Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2026},
  doi = {10.1111/jog.70289}
}
Kostenlos starten →